REFERENCES
1. Castagnola E, Mesini A. Antifungal Prophylaxis in Children Receiving
Antineoplastic Chemotherapy. Curr Fungal Infect Rep. 2018;12(2):78–85.
2. Lehrnbecher T. Antifungal prophylaxis in pediatric patients
undergoing therapy for cancer: drugs and dosing. Curr Opin Infect Dis.
2015;28(6):523–31.
3. Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference
on Infections in Leukaemia (ECIL-4): guidelines for diagnosis,
prevention, and treatment of invasive fungal diseases in paediatric
patients with cancer or allogeneic haemopoietic stem-cell
transplantation. Lancet Oncol. 2014;15(8):e327-340.
4. Ullmann AJ, Schmidt-Hieber M, Bertz H, et al. Infectious diseases in
allogeneic haematopoietic stem cell transplantation: prevention and
prophylaxis strategy guidelines 2016. Ann Hematol. 2016;95(9):1435–55.
5. Vicenzi EB, Cesaro S. Posaconazole in immunocompromised pediatric
patients. Expert Rev Anti Infect Ther. 2018;16(7):543–53.
6. Döring M, Cabanillas Stanchi KM, Queudeville M, et al. Efficacy,
safety and feasibility of antifungal prophylaxis with posaconazole
tablet in paediatric patients after haematopoietic stem cell
transplantation. J Cancer Res Clin Oncol. 2017;143(7):1281–92.
7. Arrieta AC, Sung L, Bradley JS, et al. A non-randomized trial to
assess the safety, tolerability, and pharmacokinetics of posaconazole
oral suspension in immunocompromised children with neutropenia. PloS
One. 2019;14(3):e0212837.
8. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of
invasive fungal disease from the European Organization for Research and
Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the
National Institute of Allergy and Infectious Diseases Mycoses Study
Group (EORTC/MSG) Consensus Group. Clin Infect Dis Off Publ Infect Dis
Soc Am. 2008;46(12):1813–21.
9. Gwee A, Cranswick N, Curtis N. Posaconazole: promising but
problematic in practice in pediatric patients. Pediatr Infect Dis J.
2015;34(6):604–6.
10. Döring M, Eikemeier M, Cabanillas Stanchi KM, et al. Antifungal
prophylaxis with posaconazole vs. fluconazole or itraconazole in
pediatric patients with neutropenia. Eur J Clin Microbiol Infect Dis.
2015;34(6):1189–200.
11. Döring M, Blume O, Haufe S, et al. Comparison of itraconazole,
voriconazole, and posaconazole as oral antifungal prophylaxis in
pediatric patients following allogeneic hematopoietic stem cell
transplantation. Eur J Clin Microbiol Infect Dis. 2014;33(4):629–38.
12. Valenzuela R, García P, Barraza M, et al. [Pharmacokinetics of
posaconazol in the prophylaxis and treatment of invasive fungal
infection in immunocompromised children in a pediatric hospital]. Rev
Chil Infectologia Organo Of Soc Chil Infectologia. 2018;35(1):15–21.
13. Boonsathorn S, Cheng I, Kloprogge F, et al. Clinical
Pharmacokinetics and Dose Recommendations for Posaconazole in Infants
and Children. Clin Pharmacokinet. 2019;58(1):53–61.
14. Dolton MJ, Brüggemann RJM, Burger DM, et al. Understanding
variability in posaconazole exposure using an integrated population
pharmacokinetic analysis. Antimicrob Agents Chemother.
2014;58(11):6879–85.
15. Sienkiewicz-Oleszkiewicz B, Urbańczyk K, Stachowiak M, et al.
Factors Influencing the Safety and Efficiency of Antifungal Prophylaxis
with Posaconazole in Children with Hematological Diseases: From Genetics
to Polypharmacotherapy. Indian J Hematol Blood Transfus.
2019;35(4):699–706.
16. Döring M, Müller C, Johann P-D, et al. Analysis of posaconazole as
oral antifungal prophylaxis in pediatric patients under 12 years of age
following allogeneic stem cell transplantation. BMC Infect Dis.
2012;12:263.
17. Döring M, Cabanillas Stanchi KM, Klinker H, et al. Posaconazole
plasma concentrations in pediatric patients receiving antifungal
prophylaxis during neutropenia. Med Mycol. 2017;55(4):375–84.
18. Ramos JT, Romero CA, Belda S, et al. Clinical practice update of
antifungal prophylaxis in immunocompromised children. Rev Esp Quimioter.
2019;32(5):410–25.
19. Jancel T, Shaw PA, Hallahan CW, et al. Therapeutic drug monitoring
of posaconazole oral suspension in paediatric patients younger than 13
years of age: a retrospective analysis and literature review. J Clin
Pharm Ther. 2017;42(1):75–9.